171 related articles for article (PubMed ID: 11897594)
1. Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapy.
Kantor R; Fessel WJ; Zolopa AR; Israelski D; Shulman N; Montoya JG; Harbour M; Schapiro JM; Shafer RW
Antimicrob Agents Chemother; 2002 Apr; 46(4):1086-92. PubMed ID: 11897594
[TBL] [Abstract][Full Text] [Related]
2. Drug resistance mutations and outcome of second-line treatment in patients with first-line protease inhibitor failure on nelfinavir-containing HAART.
Røge BT; Katzenstein TL; Nielsen HL; Gerstoft J
HIV Med; 2003 Jan; 4(1):38-47. PubMed ID: 12534958
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of HIV protease mutations on failure of nelfinavir-containing HAART: a retrospective analysis of four clinical studies and two observational cohorts.
Clotet B; Ruiz L; Martinez-Picado J; Negredo E; Hill A; Popescu M
HIV Clin Trials; 2002; 3(4):316-23. PubMed ID: 12187506
[TBL] [Abstract][Full Text] [Related]
4. N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure.
Mitsuya Y; Winters MA; Fessel WJ; Rhee SY; Hurley L; Horberg M; Schiffer CA; Zolopa AR; Shafer RW
AIDS Res Hum Retroviruses; 2006 Dec; 22(12):1300-5. PubMed ID: 17209774
[TBL] [Abstract][Full Text] [Related]
5. Diverse pattern of protease inhibitor resistance mutations in HIV-1 infected patients failing nelfinavir.
Svedhem V; Lindkvist A; Bergroth T; Knut L; Sönnerborg A
J Med Virol; 2005 Aug; 76(4):447-51. PubMed ID: 15977242
[TBL] [Abstract][Full Text] [Related]
6. Interference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency virus type 1.
Sugiura W; Matsuda Z; Yokomaku Y; Hertogs K; Larder B; Oishi T; Okano A; Shiino T; Tatsumi M; Matsuda M; Abumi H; Takata N; Shirahata S; Yamada K; Yoshikura H; Nagai Y
Antimicrob Agents Chemother; 2002 Mar; 46(3):708-15. PubMed ID: 11850252
[TBL] [Abstract][Full Text] [Related]
7. Resistance-associated mutations in the human immunodeficiency virus type 1 subtype c protease gene from treated and untreated patients in the United Kingdom.
Cane PA; de Ruiter A; Rice P; Wiselka M; Fox R; Pillay D
J Clin Microbiol; 2001 Jul; 39(7):2652-4. PubMed ID: 11427587
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic cross-resistance to nelfinavir: the role of prior antiretroviral therapy and the number of mutations in the protease gene.
Dronda F; Casado JL; Moreno S; Hertogs K; García-Arata I; Antela A; Pérez-Elías MJ; Ruiz L; Larder B;
AIDS Res Hum Retroviruses; 2001 Feb; 17(3):211-5. PubMed ID: 11177403
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M;
Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623
[TBL] [Abstract][Full Text] [Related]
10. Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors.
Svicher V; Ceccherini-Silberstein F; Erba F; Santoro M; Gori C; Bellocchi MC; Giannella S; Trotta MP; Monforte Ad; Antinori A; Perno CF
Antimicrob Agents Chemother; 2005 May; 49(5):2015-25. PubMed ID: 15855527
[TBL] [Abstract][Full Text] [Related]
11. Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapy.
Servais J; Lambert C; Fontaine E; Plesséria JM; Robert I; Arendt V; Staub T; Schneider F; Hemmer R; Burtonboy G; Schmit JC
J Clin Microbiol; 2001 Feb; 39(2):454-9. PubMed ID: 11158089
[TBL] [Abstract][Full Text] [Related]
12. The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients.
Turner D; Schapiro JM; Brenner BG; Wainberg MA
Antivir Ther; 2004 Jun; 9(3):301-14. PubMed ID: 15259893
[TBL] [Abstract][Full Text] [Related]
13. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.
Schapiro JM; Winters MA; Lawrence J; Merigan TC
AIDS; 1999 Feb; 13(3):359-65. PubMed ID: 10199226
[TBL] [Abstract][Full Text] [Related]
14. Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy.
Santoro MM; Svicher V; Gori C; Zaccarelli M; Tozzi V; Forbici F; D'Arrigo R; Trotta MP; Bellocchi MC; Visco-Comandini U; Cenci A; Bertoli A; Narciso P; Antinori A; Perno CF; Ceccherini-Silberstein F
New Microbiol; 2006 Apr; 29(2):89-100. PubMed ID: 16841549
[TBL] [Abstract][Full Text] [Related]
15. Emergence of protease inhibitor resistance mutations in human immunodeficiency virus type 1 isolates from patients and rapid screening procedure for their detection.
Vasudevachari MB; Zhang YM; Imamichi H; Imamichi T; Falloon J; Salzman NP
Antimicrob Agents Chemother; 1996 Nov; 40(11):2535-41. PubMed ID: 8913459
[TBL] [Abstract][Full Text] [Related]
16. Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir.
Grossman Z; Paxinos EE; Averbuch D; Maayan S; Parkin NT; Engelhard D; Lorber M; Istomin V; Shaked Y; Mendelson E; Ram D; Petropoulos CJ; Schapiro JM
Antimicrob Agents Chemother; 2004 Jun; 48(6):2159-65. PubMed ID: 15155216
[TBL] [Abstract][Full Text] [Related]
17. Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study.
Lorenzi P; Opravil M; Hirschel B; Chave JP; Furrer HJ; Sax H; Perneger TV; Perrin L; Kaiser L; Yerly S
AIDS; 1999 Feb; 13(2):F17-21. PubMed ID: 10202819
[TBL] [Abstract][Full Text] [Related]
18. Persistence of mutations during replication of an HIV library containing combinations of selected protease mutations.
Song W; Maeda Y; Tenpaku A; Harada S; Yusa K
Antiviral Res; 2004 Mar; 61(3):173-80. PubMed ID: 15168798
[TBL] [Abstract][Full Text] [Related]
19. Genetic variation and susceptibilities to protease inhibitors among subtype B and F isolates in Brazil.
Tanuri A; Vicente AC; Otsuki K; Ramos CA; Ferreira OC; Schechter M; Janini LM; Pieniazek D; Rayfield MA
Antimicrob Agents Chemother; 1999 Feb; 43(2):253-8. PubMed ID: 9925514
[TBL] [Abstract][Full Text] [Related]
20. Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment.
Winters MA; Schapiro JM; Lawrence J; Merigan TC
J Virol; 1998 Jun; 72(6):5303-6. PubMed ID: 9573309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
